InVivoSIM anti-human LAG-3 (Relatlimab Biosimilar)
Catalog #SIM0015
Clone:
Relatlimab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Relatlimab making it ideal for research use. This Relatlimab biosimilar reacts with human LAG-3 also known as CD223. LAG-3 is a 70 kDa type I transmembrane glycoprotein encoded by the Lag3 gene that belongs to the immunoglobulin superfamily. LAG-3 is expressed by activated T lymphocytes, NK cells, and T regulatory cells. LAG-3ās main ligand is MHC class II which it binds to with a higher affinity than even CD4 does. Upon binding LAG-3 is thought to play similar roles as CTLA-4 and PD-1 including downregulation of TCR signaling and inhibition of CD4-dependent T cell function. LAG-3 has also been demonstrated to contribute to the suppressor function of T regulatory cells. In contrast to inhibition, LAG-3 has been shown to promotes immune responses by activating antigen-presenting cells.Ā Relatlimab is a LAG-3 inhibitor. A combination of Relatlimab with the immunomodulatory drug lenalidomide significantly increases IL-2 production by T cells and antibody-dependent cytotoxicity mediated by NK cells.Specifications
Isotype | Human IgG4, Īŗ |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Human LAG-3 |
Reported Applications | ELISA |
Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
Sterility | 0.2 Āµm filtration |
Purification | Protein A |
RRID | AB_2927531 |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |